RSLS — ReShape Lifesciences Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapValue Trap

Annual cashflow statement for ReShape Lifesciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-23.7	-12.3	-61.9	-46.2	-11.4
Depreciation
Amortisation
Deferred Taxes
Non-Cash Items	3.59	2.98	47.4	21.9	2.26
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-3.26	-1.4	-2.74	0.709	-8.01
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-22.9	-10.4	-15.4	-21.9	-17
Capital Expenditures	-0.194	-0.171	-0.352	-0.131	-0.043
Purchase of Fixed Assets
Other Investing Cash Flow Items	2.55	0	2.21	0.039	0.033
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities	2.36	-0.171	1.85	-0.092	-0.01
Financing Cash Flow Items	0	—	-3.23	0	—
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	13.4	0.43	33.3	3.13	17.6
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-7.13	-10.2	19.8	-18.9	0.604